Loading insider details...
Beta
Latest Form 4 (Jan 21, 2026): Grant/Award of 18,724 QNCX shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 21, 2026 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 18,724 | n/a |
| Jan 13, 2026 | BioXcel Therapeutics, Inc. (BTAI) | Grant/Award | 17,000 | n/a |
| Jun 6, 2025 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 27,000 | n/a |
| Jan 9, 2025 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 30,282 | n/a |
| Jun 11, 2024 | BioXcel Therapeutics, Inc. (BTAI) | Grant/Award | 17,000 | n/a |
| Jun 8, 2024 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 27,000 | n/a |
| Jun 28, 2023 | BioXcel Therapeutics, Inc. (BTAI) | Grant/Award | 17,000 | n/a |
| May 26, 2023 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 27,000 | n/a |
| Jun 10, 2022 | Cortexyme, Inc. (CRTX) | Grant/Award | 54,000 | n/a |
| May 23, 2022 | BioXcel Therapeutics, Inc. (BTAI) | Grant/Award | 17,000 | n/a |